Optellum and GE Healthcare recently announced a collaboration to advance precision diagnosis and treatment of lung cancer. GE Healthcare is a leading provider of medical imaging solutions. Optellum is a leader in artificial intelligence (AI) decision support to help diagnose lung cancer early and treat it optimally.
Václav Potěšil, Ph.D., Founder and Chief Business Officer of Optellum, said, “This collaboration is a major step forward for Optellum and the field of thoracic oncology at large. GE’s vast clinical network can accelerate deployment of Optellum’s platform and could enable a revolutionary redefinition of early lung cancer treatment for clinicians and patients around the world.”
As part of their partnership, the companies will help to address the biggest challenge in the diagnosis of lung cancer: identifying whether a nodule is cancerous or benign. Many incidentally detected pulmonary nodules are associated with indeterminate cancer risk, and they are extremely challenging for clinicians to diagnose and manage, resulting in delays in cancer treatment and invasive procedures in healthy people.
Ben Newton, General Manager, Oncology Solutions, at GE Healthcare, said, “The precise diagnosis of lung cancer can greatly improve patient prognosis. The integration of imaging and medical device data from the Edison Platform with AI-enabled solutions like the one offered by the Optellum Virtual Nodule Clinic has the potential to streamline clinician workflows and advance our goal of making precision healthcare, taking the right action at the right time for every patient, at scale, as widely accessible as possible.”
The GE Healthcare team will collaborate with Optellum’s sales team to distribute the Virtual Nodule Clinic and work with Optellum to integrate the platform with AI solutions powered by the Edison platform. GE Healthcare plans to integrate Optellum’s Lung Cancer Prediction AI into its existing workflow, including CT and PACS.
